Sebastian Burgis

Sebastian Burgis

Associate, Capital Markets


Sebastian Burgis primarily focuses on capital markets transactions and corporate matters, advising clients in a variety of industries. His recent significant representations include: 

  • MorphoSys AG in:
    • its pending €2.7 billion sale to, and public takeover by, Novartis and the simultaneous disposition of the worldwide marketing rights of its antibody drug Monjuvi to Incyte Corporation
    • connection with a cash capital increase with gross proceeds of approximately €102.7 million and the issuance of a US$300 million development funding bond
  • Armira in its €30 million anchor investment as part of a €60 million private placement of new shares in tonies SE
  • Silver Lake in its strategic partnership and investment in German publicly listed company Software AG via the purchase of €344 million aggregate principal amount of subordinated unsecured convertible notes. This is the first PIPE by any U.S. technology investment firm in a German public company
  • Berenberg as sole global coordinator and joint bookrunner and Stifel as additional joint bookrunner in connection with a capital increase of Pacifico Renewables Yield AG
  • Deutsche Bank, Goldman Sachs and J.P. Morgan as joint bookrunners in the €842 million private placement of ordinary bearer shares and listing on the Frankfurt Stock Exchange of ABOUT YOU Holding AG
  • SIGNA Sports United GmbH in connection with its US$3.3 billion initial public offering on the New York Stock Exchange as a result of the de-SPAC merger with Yucaipa Acquisition Corporation. The merger also included the acquisition of WiggleCRC Group

Prior to joining Skadden, Mr. Burgis gained experience as a law clerk in the Frankfurt and Brussels offices of other international law firms.



  • Second State Exam, Higher Regional Court Bamberg, 2019
  • First State Exam, University of W├╝rzburg School of Law, 2016


  • Frankfurt am Main


  • English
  • German

Sebastian Burgis